Attention deficit hyperactivity disorder - symptoms, diagnosis and therapy among children and adults.
DOI:
https://doi.org/10.12775/JEHS.2023.37.01.012Keywords
attention deficit hyperactivity, ADHD, methylphenidate, ADHD diagnostic, ADHD treatment, atomoxetineAbstract
Introduction: The prevalence of Attention Deficit Hyperactivity Disorder (ADHD) in the world is estimated at about 5%. Among adults, it occurs with a frequency of 2.5%. This syndrome can significantly impair functioning in various areas of life. There is a treatment to reduce the symptoms.
Aim of the study: The aim of the study was to collect and analyze publications on attention deficit hyperactivity disorder - symptoms, diagnosis and therapy, taking into account the differences among children and adults.
Material and methods: We reviewed the literature available in the PubMed database using the keywords: "ADHD"; "Attention deficit hyperactivity disorder"; '' ADHD diagnosis', ''ADHD therapy'; ‘’ADHD drug therapy’, ‘’Methylphenidate’, ‘’Atomoxetine”
Results: The clinical presentation of the disorder changes over the years. The main symptoms among children are related to inattention and impulsiveness, while among adults, hyperactivity can turn into a feeling of inner fear. Among children, frequent accompanying disorders are behavioral and oppositional-defiant disorders, and among adults, sleep disorders, personality, mood and anxiety disorders. ADHD treatment is based on a multimodal approach that uses cognitive behavioral therapy and effective stimulants (methylphenidate) and non-stimulants (atomoxetine) among children and adults.
Conclusions: There are differences in symptoms, comorbidities and diagnosis of ADHD among children and adults. Pharmacotherapy is carried out using the same drugs that are safe and effective. Diagnosis of the disorder and both non-pharmacological and pharmacological help are important due to the risk of increased mortality in patients.
References
Polanczyk G, de Lima MS, Horta BL et al. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007 Jun;164(6):942-8. doi: 10.1176/ajp.2007.164.6.942. PMID: 17541055.
Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006 Feb;36(2):159-65. doi: 10.1017/S003329170500471X. PMID: 16420712.
Thapar A, Cooper M. Attention deficit hyperactivity disorder. Lancet. 2016 Mar 19;387(10024):1240-50. doi: 10.1016/S0140-6736(15)00238-X. Epub 2015 Sep 17. PMID: 26386541.
Heidbreder R. ADHD symptomatology is best conceptualized as a spectrum: a dimensional versus unitary approach to diagnosis. Atten Defic Hyperact Disord. 2015 Dec;7(4):249-69. doi: 10.1007/s12402-015-0171-4. Epub 2015 May 10. PMID: 25957598.
Biederman J, Kwon A, Aleardi M et al. Absence of gender effects on attention deficit hyperactivity disorder: findings in nonreferred subjects. Am J Psychiatry. 2005 Jun;162(6):1083-9. doi: 10.1176/appi.ajp.162.6.1083. PMID: 15930056.
Williamson D, Johnston C. Gender differences in adults with attention-deficit/hyperactivity disorder: A narrative review. Clin Psychol Rev. 2015 Aug;40:15-27. doi: 10.1016/j.cpr.2015.05.005. Epub 2015 May 27. PMID: 26046624.
Bálint S, Czobor P, Komlósi S et al. Attention deficit hyperactivity disorder (ADHD): gender- and age-related differences in neurocognition. Psychol Med. 2009 Aug;39(8):1337-45. doi: 10.1017/S0033291708004236. Epub 2008 Aug 20. PMID: 18713489.
Rasmussen K., Levander S. Untreated ADHD in adults: Are there sex differences in symptoms, comorbidity, and impairment? J. Atten. Disord. 2009;12:353–360. doi: 10.1177/1087054708314621.
Spencer TJ, Biederman J, Mick E. Attention-deficit/hyperactivity disorder: diagnosis, lifespan, comorbidities, and neurobiology. Ambul Pediatr. 2007 Jan-Feb;7(1 Suppl):73-81. doi: 10.1016/j.ambp.2006.07.006. PMID: 17261486.
Dalsgaard S, Leckman JF, Mortensen PB et al. Effect of drugs on the risk of injuries in children with attention deficit hyperactivity disorder: a prospective cohort study. Lancet Psychiatry. 2015 Aug;2(8):702-709. doi: 10.1016/S2215-0366(15)00271-0. Epub 2015 Jul 22. PMID: 26249301.
Peasgood T, Bhardwaj A, Biggs K et al. The impact of ADHD on the health and well-being of ADHD children and their siblings. Eur Child Adolesc Psychiatry. 2016 Nov;25(11):1217-1231. doi: 10.1007/s00787-016-0841-6. Epub 2016 Apr 1. PMID: 27037707; PMCID: PMC5083759.
Harstad E, Levy S; Committee on Substance Abuse. Attention-deficit/hyperactivity disorder and substance abuse. Pediatrics. 2014 Jul;134(1):e293-301. doi: 10.1542/peds.2014-0992. PMID: 24982106.
Adler LA. Clinical presentations of adult patients with ADHD. J Clin Psychiatry. 2004;65 Suppl 3:8-11. PMID: 15046529.
Taurines R, Schmitt J, Renner T et al. Developmental comorbidity in attention-deficit/hyperactivity disorder. Atten Defic Hyperact Disord. 2010 Dec;2(4):267-89. doi: 10.1007/s12402-010-0040-0. Epub 2010 Nov 10. PMID: 21432612.
Jacob CP, Romanos J, Dempfle A et al. Co-morbidity of adult attention-deficit/hyperactivity disorder with focus on personality traits and related disorders in a tertiary referral center. Eur Arch Psychiatry Clin Neurosci. 2007 Sep;257(6):309-17. doi: 10.1007/s00406-007-0722-6. Epub 2007 Apr 1. PMID: 17401730.
APA. Diagnostic and statistical manual of mental disorders (5th ed). Arlington, VA: American Psychiatric Publishing. 2013.
Abrams J, Faraone SV, Woodworth KY et al. Are Adult ADHD Patients Good Informants of Their Symptoms? A Qualitative Literature Review of Concordance Between Clinician and Self-Report ADHD Symptoms. J Nerv Ment Dis. 2018 Sep;206(9):739-743. doi: 10.1097/NMD.0000000000000870. PMID: 30124570; PMCID: PMC7135925.
Silverstein MJ, Faraone SV, Alperin S et al. How Informative Are Self-Reported Adult Attention-Deficit/Hyperactivity Disorder Symptoms? An Examination of the Agreement Between the Adult Attention-Deficit/Hyperactivity Disorder Self-Report Scale V1.1 and Adult Attention-Deficit/Hyperactivity Disorder Investigator Symptom Rating Scale. J Child Adolesc Psychopharmacol. 2018 Jun;28(5):339-349. doi: 10.1089/cap.2017.0082. Epub 2017 Nov 27. PMID: 29172673.
Austerman J. ADHD and behavioral disorders: Assessment, management, and an update from DSM-5. Cleve Clin J Med. 2015 Nov;82(11 Suppl 1):S2-7. doi: 10.3949/ccjm.82.s1.01. PMID: 26555810.
Attention deficit hyperactivity disorder: diagnosis and management. London: National Institute for Health and Care Excellence (NICE); 2019 Sep. PMID: 29634174.
Muñoz-Solomando A, Kendall T, Whittington CJ. Cognitive behavioural therapy for children and adolescents. Curr Opin Psychiatry. 2008 Jul;21(4):332-7. doi: 10.1097/YCO.0b013e328305097c. PMID: 18520736.
Plessen KJ, Bansal R, Zhu H et al. Hippocampus and amygdala morphology in attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2006 Jul;63(7):795-807. doi: 10.1001/archpsyc.63.7.795. PMID: 16818869; PMCID: PMC2367150.
Cortese S. The neurobiology and genetics of Attention-Deficit/Hyperactivity Disorder (ADHD): what every clinician should know. Eur J Paediatr Neurol. 2012 Sep;16(5):422-33. doi: 10.1016/j.ejpn.2012.01.009. Epub 2012 Feb 2. PMID: 22306277.
Posner J, Polanczyk GV, Sonuga-Barke E. Attention-deficit hyperactivity disorder. Lancet. 2020 Feb 8;395(10222):450-462. doi: 10.1016/S0140-6736(19)33004-1. Epub 2020 Jan 23. PMID: 31982036; PMCID: PMC7880081.
Bymaster FP, Katner JS, Nelson DL et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002 Nov;27(5):699-711. doi: 10.1016/S0893-133X(02)00346-9. PMID: 12431845.
Eli Lilly and Company. Strattera® (atomoxetine hydrochloride) - Prescribing information. Retrieved October 29, 2020.
Therapeutic Goods Administration. Strattera® (atomoxetine hydrochloride) - Australian prescribing information. Retrieved October 29, 2020.
Duong S, Chung K, Wigal SB. Metabolic, toxicological, and safety considerations for drugs used to treat ADHD. Expert Opin Drug Metab Toxicol. 2012 May;8(5):543-52. doi: 10.1517/17425255.2012.671295. Epub 2012 Mar 13. PMID: 22413882.
Cooper WO, Habel LA, Sox CM et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med. 2011 Nov 17;365(20):1896-904. doi: 10.1056/NEJMoa1110212. Epub 2011 Nov 1. PMID: 22043968; PMCID: PMC4943074.
Habel LA, Cooper WO, Sox CM et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA. 2011 Dec 28;306(24):2673-83. doi: 10.1001/jama.2011.1830. Epub 2011 Dec 12. PMID: 22161946; PMCID: PMC3350308.
Fredriksen M, Halmøy A, Faraone SV et al. Long-term efficacy and safety of treatment with stimulants and atomoxetine in adult ADHD: a review of controlled and naturalistic studies. Eur Neuropsychopharmacol. 2013 Jun;23(6):508-27. doi: 10.1016/j.euroneuro.2012.07.016. Epub 2012 Aug 20. PMID: 22917983.
Faraone SV, Banaschewski T, Coghill D et al. The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder. Neurosci Biobehav Rev. 2021 Sep;128:789-818. doi: 10.1016/j.neubiorev.2021.01.022. Epub 2021 Feb 4. PMID: 33549739; PMCID: PMC8328933.
Ljung T, Chen Q, Lichtenstein P, Larsson H. Common etiological factors of attention-deficit/hyperactivity disorder and suicidal behavior: a population-based study in Sweden. JAMA Psychiatry. 2014 Aug;71(8):958-64. doi: 10.1001/jamapsychiatry.2014.363. PMID: 24964928.
Dalsgaard S, Leckman JF, Mortensen PB et al. Effect of drugs on the risk of injuries in children with attention deficit hyperactivity disorder: a prospective cohort study. Lancet Psychiatry. 2015 Aug;2(8):702-709. doi: 10.1016/S2215-0366(15)00271-0. Epub 2015 Jul 22. PMID: 26249301
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Agata Surowiec, Katarzyna Dobko, Gabriela Frącz, Agata Glac, Klaudia Kuliga, Kinga Musz, Natalia Sejnowska, Agnieszka Socha, Kinga Śnieżek, Anna Zając
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 586
Number of citations: 0